Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients

Inclusion Criteria: * Patients whose parents or guardians can issue informed consent * Patients aged over 7 and less than 16 at the baseline * Patients confirmed to show type I allergy * Patients with allergic conjunctivitis * Patients having subjective symptoms at the baseline (itching sensation, foreign body sensation, eye pain, etc.) Exclusion Criteria: * Patients having ocular itching sensation and injection caused by disease other than allergic conjunctivitis * Patients having retinal detachment, diabetic retinopathy or progressive retinal disease * Patients with a history of ocular infection, corneal herpes or relapsing corneal erosion of sudden onset or secondary to corneal injury * Patients having received continuous treatment with corticosteroid within 3 months * Patients having received immunotherapy * Patients requiring continuous treatment of corticosteroid, immunosuppressors, non-steroidal anti-inflammatory agents, vasoconstrictors, anti-histamines, anti-allergy agents, herbal preparations indicated for "conjunctivitis" or any ophthalmic solution other than the test product * Patients having undergone ocular laser therapy within 3 months * Unilaterally blind patients (best corrected visual acuity: below 0.01) * Patients with a history of allergy or hypersensitivity to olopatadine hydrochloride * Patients necessitating the use of contact lens during the study period * Other patients judged by the attending physician as inappropriate for study